Synonyms: SB-683699 | SB683699
Compound class:
Synthetic organic
Comment: Firategrast (SB-683699) is an orally bioavailable, short-acting small molecule α4-integrin antagonist. It was designed to reduce α4β1/α4β7 integrin-mediated trafficking of lymphocytes into the central nervous system (CNS). Anti-α4-integrin natalizumab is currently approved to treat MS, but its long half-life is problematic, and it has to be administered by infusion. This short acting small molecule was developed as an alternative to antibody therapy.
|
|
No information available. |
Summary of Clinical Use ![]() |
Phase 2 clinical trials of firategrast in MS and Crohn's disease have been completed. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00395317 | Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) | Phase 2 Interventional | GlaxoSmithKline | 2 | |
NCT00101946 | Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease | Phase 2 Interventional | GlaxoSmithKline |